| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 63, 550-557, Copyright © 1986 by Endocrine Society
ARTICLES |
C Monder, CH Shackleton, HL Bradlow, MI New, E Stoner, F Iohan and V Lakshmi
We describe the metabolism of cortisol (F) in three children, two of them siblings, with apparent mineralocorticoid excess (AME). As with prior patients with AME, oxidation of F to cortisone (E) was impaired, but reduction of E to F was not. We propose that this metabolic defect is caused by deficient 11-dehydrogenase associated with unimpaired 11- reductase. The following supporting observations were made: urinary C21 11-hydroxy metabolites exceeded C21 11-oxo metabolites: ratio of urinary cortols to cortolones, 6.6 +/- 2.8 (+/- SD; normal, 0.47); tetrahydrocortisol (THF) and alloTHF to tetrahydrocortisone, 14.6 +/- 5.6 (normal, approximately 1); normal subjects oxidized [11 alpha-3H]F with transfer of 3H to water; the patients did not; 11-hydroxy, but not 11-oxo, C19 steroids were excreted into the urine; and fibroblasts from patients had 5 times more 11-reductase activity than normal subjects, though fibroblasts from neither group had 11-dehydrogenase activity. Other defects of cortisol metabolism not directly associated with 11- dehydrogenase deficiency were found: impaired conversion of tetrahydro to hexahydro neutral steroids, indicating defective reductive metabolism of the side chain; depressed F production rate and increased half-life of circulating F, resulting in normal blood levels of F; increased excretion of unconjugated F metabolites; and decreased excretion of THF relative to alloTHF, consistent with a 5 beta- reductase defect. Excretion of acidic metabolites of F (cortoic acids) was within the normal range. However, little or no 20 beta-hydroxy acids were excreted, while the level of urinary 20 alpha-hydroxy acids was increased. The 11-hydroxy to 11-oxo ratio of acid metabolites was similar to values in normal subjects. The proportion of cortoic acids relative to neutral hexahydro metabolites was increased (0.37 to 1.27 in patients; 22 in normal subjects). We conclude that children with AME have multiple defects in the conversion of F to neutral metabolites, while metabolism to cortoic acids was less extensively affected. How the defects in cortisol metabolism and the symptoms of AME are related remains to be determined.
This article has been cited by other articles:
![]() |
M. A. Bailey, J. M. Paterson, P. W.F. Hadoke, N. Wrobel, C. O.C. Bellamy, D. G. Brownstein, J. R. Seckl, and J. J. Mullins A Switch in the Mechanism of Hypertension in the Syndrome of Apparent Mineralocorticoid Excess J. Am. Soc. Nephrol., January 1, 2008; 19(1): 47 - 58. [Full Text] [PDF] |
||||
![]() |
M. Quinkler, D. Zehnder, J. Lepenies, M. D Petrelli, J. S Moore, S. V Hughes, P. Cockwell, M. Hewison, and P. M Stewart Expression of renal 11{beta}-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function Eur. J. Endocrinol., August 1, 2005; 153(2): 291 - 299. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Draper and P. M Stewart 11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action J. Endocrinol., August 1, 2005; 186(2): 251 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Quinkler and P. M. Stewart Hypertension and the Cortisol-Cortisone Shuttle J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2384 - 2392. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Odermatt, B. Dick, P. Arnold, T. Zaehner, V. Plueschke, M. N. Deregibus, H. Repetto, B. M. Frey, F. J. Frey, and P. Ferrari A Mutation in the Cofactor-Binding Domain of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1247 - 1252. [Abstract] [Full Text] |
||||
![]() |
M. I. New and R. C. Wilson Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess PNAS, October 26, 1999; 96(22): 12790 - 12797. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lovati, P. Ferrari, B. Dick, K. Jostarndt, B. M. Frey, F. J. Frey, U. Schorr, and A. M. Sharma Molecular Basis of Human Salt Sensitivity: The Role of the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3745 - 3749. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Morineau, J.-M. Marc, A. Boudi, H. Galons, M. Gourmelen, P. Corvol, L. Pascoe, and J. Fiet Genetic, Biochemical, and Clinical Studies of Patients With A328V or R213C Mutations in 11{beta}HSD2 Causing Apparent Mineralocorticoid Excess Hypertension, September 1, 1999; 34(3): 435 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Wilson, S. Dave-Sharma, J.-Q. Wei, V. R. Obeyesekere, K. Li, P. Ferrari, Z. S. Krozowski, C. H. L. Shackleton, L. Bradlow, T. Wiens, et al. A genetic defect resulting in mild low-renin hypertension PNAS, August 18, 1998; 95(17): 10200 - 10205. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dave-Sharma, R. C. Wilson, M. D. Harbison, R. Newfield, M. R. Azar, Z. S. Krozowski, J. W. Funder, C. H. L. Shackleton, H. L. Bradlow, J.-Q. Wei, et al. Examination of Genotype and Phenotype Relationships in 14 Patients with Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2244 - 2254. [Abstract] [Full Text] |
||||
![]() |
S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension Cardiovasc Res, April 1, 1998; 38(1): 16 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Morris, Y. H. Lo, W. R. Lichtfield, and G. H. Williams Impact of Dietary Na+ on Glycyrrhetinic Acid-Like Factors (Kidney 11{beta}-(HSD2)-GALFs) in Human Essential Hypertension Hypertension, January 1, 1998; 31(1): 469 - 472. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |